kamada.com - KMDA Profit before deduction of interest, taxes, depreciation and amortization

Public company logo of Kamada (KMDA)

Kamada Ltd. enjoys global recognition in the therapy of orphan diseases, as confirmed by its current EBITDA. The value of 46.04 defines the current level of this metric. Growth is driven by the sale of plasma products and a contract with Takeda. Stability is ensured by a strict raw material transportation protocol utilizing specialized carriers, which eliminates disruptions in the supply of finished medications.

kamada.com (KMDA) Operating profit EBITDA: for the period 11/23/2025 - 11/11/2026

Summary analytical data breakdowns for Kamada (KMDA)

- stock value and consensus price forecast:
Market Chart Kamada Pharma|KMDA - Consensus Target
- issuer market value details:
Market Valuation Kamada|KMDA - Enterprise Value
- book capitalization indicators:
Net Asset Value per Share Kamada|KMDA - Book Capitalization|Capitalization to Book Value Ratio kamada.com|KMDA - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Kamada Ltd.|KMDA - Long-Term Debt to Equity|Current Liabilities to Equity Kamada Ltd|KMDA - Company Aggregate Debts|Debt to Net Assets Ratio Kamada|KMDA - Company Long-Term Debts|Company Short-Term Debts Kamada|Intermediate Coverage Ratio kamada.com
- earnings and market multiples details:
KMDA - Company Net Income|Future Profit Kamada Ltd.|KMDA - P/E Multiple|Forward P/E Multiple kamada.com|KMDA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Kamada|KMDA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kamada|KMDA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months kamada.com|KMDA - Earnings growth in current year|Earnings growth forecast for next year Kamada Ltd.
Summary company analytics:Kamada Pharma
Brand item of kamada.com

Kamada Ltd. (KMDA) maintains a monopoly status in the plasmapheresis segment, and the high cost of orphan drugs ensures a stable inflow of liquidity. An analysis of cash operating profit before deductions allows for an assessment of the daily volume of actual funds from core operations excluding depreciation and taxes, confirming the business's fundamental stability and its ability to generate free cash flow.

Who Kamada Ltd. competes with

Operating income before deduction of amortization Vertex Corp (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BioMarin Pharmaceutical Inc. (BMRN)|BBIO (BridgeBio Pharma Inc) - Operating profit EBITDA|Operating profit before amortization BGM (BGM Group Corp)|Operating profit before deduction of amortization COGT (Cogent Biosciences)|XERS (xerispharma.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Keros Therapeutics, Inc. KROS|ARCT (Arcturus Therapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Eton Pharma - Operating profit EBITDA|Income before deduction of interest, taxes and amortization FULC (Fulcrum Corp)|ABEO: Operating profit EBITDA|Mereo BioPharma Group plc (MREO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Protalix BioTherapeutics, Inc.|PLRX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Applied Therapeutics (APLT)|Operating profit before deduction of amortization Aileron Therapeutics RNTX|Operating profit EBITDA GELS (Gelteq)|Operating profit EBITDA Aytu BioPharma Inc AYTU|CMMB - Profit before payment of interest, taxes and amortization|SRXH - Operating profit EBITDA|PLRZ: Operating profit EBITDA|Aeterna Zentaris Inc. (AEZS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Cyclo Therapeutics|Operating profit before deduction of amortization Inozyme (INZY)|Operating profit EBITDA RPHM|Operating profit EBITDA COSCIENS Biopharma Inc (CSCI)